Dr. Reddy's Laboratories Ltd
. today announced the launch of Deferasirox Tablets for Oral Suspension, a therapeutically equivalent generic version of Exjade® (deferasirox) Tablets for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).
The stock is trading up more than 2% on the NSE.
The Exjade brand had US sales of approximately $113 million MAT for the most recent twelve months ending in September 2019 according to IQVIA Health*.
Dr. Reddy's Deferasirox Tablets for Oral Suspension, are available in 125 mg, 250 mg, and 500 mg dosage strengths
in bottle count sizes of 30.
Dr Reddys Laboratories Ltd is currently trading at Rs2,933.65 up by Rs63.5 or 2.21% from its previous closing of Rs2,870.15 on the BSE.